|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
With rs8099917, HCV genotype 1b patients had a significantly lower frequency of the favourable genotype (86.6 %) compared with healthy controls (91.7 %), and HCV genotype 2a patients had an intermediate frequency (89.9 %).
|
21228123 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We investigated the distribution of HCV genotypes and single-nucleotide polymorphisms (SNPs) of IL28B (rs12979860 and rs8099917) in Pakistani population.
|
25703417 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We genotyped the rs8099917 single-nucleotide polymorphism in 351 hepatitis C-associated HCC patients without history of IFN-based treatment, and correlated the age at onset of HCC in patients with each genotype.
|
23689989 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We found that the HCV genotype 1 responder genotypes at rs12979860 and rs8099917 did not associate with sustained virological response to PEG-IFN/ribavirin therapy.
|
21374656 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We determined three SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in 82 patients with chronic HCV infection treated with pegylated interferon alpha and ribavirin (peg-IFNα/RBV).
|
23314745 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We describe the genotypes and allele distribution of interleukin 28B (IL28B) rs12979860 and rs8099917 single nucleotide polymorphisms (SNPs) in hepatitis C virus (HCV) G1-4 infected patients, to assess predictive ability and to determine whether the combined determination of two IL28B SNPs might improve sustained virologic response (SVR) prediction of both in HCV mono- and HIV/HCV co-infected patients.
|
26485009 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We characterized the IL28B genotype (for rs12980275 and rs8099917) in 308 patients (mean age, 56 y; 25% African American; 38% with advanced-stage fibrosis) with genotype 1 HCV infection seen at the Michael E. DeBakey Veterans Administration Medical Center in Houston, Texas, from May 1, 2009, through April 1, 2012.
|
23978349 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
We also studied their IL28B SNP (rs8099917) genotype, since a number of investigators have found a strong association of IL28B with spontaneous or treatment induced HCV clearance.
|
27511600 |
2016 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Variants of the interleukin-28B (IL28B) gene correlate with an SVR to PR, and combined IL28B polymorphisms may improve the prediction of treatment outcome.The potential role of both rs8099917 and rs12979860 IL28B single nucleotide polymorphisms (SNPs) combined with presence of cryoglobulins in predicting SVR to PR in hepatitis C virus (HCV)-chronically infected patients was analyzed in the present study.Single and combined IL28B SNPs (rs12979860 and rs8099917) were analyzed in 64 chronic HCV patients treated with PR showing circulating cryoglobulins and compared to 108 noncryoglobulinemic subjects to verify the predictive value on the SVR.The association of rs12979860CC or rs8099917TT with SVR was confirmed in the noncryoglobulinemic group but not in cryoglobulinemic patients.
|
26334898 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two SNPs near IL28B, rs12979860 and rs8099917, were analyzed using an allelic discrimination assay in a total of 454 individuals, including 147 health-check examinees and 307 patients with HCV infection.
|
24516704 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two single nucleotide polymorphisms were genotyped in the IL28B locus (rs12979860 and rs8099917) from 817 patients with chronic HCV infection, and substitutions at amino acids 70 and 91 of the HCV core protein and within the NS5A interferon sensitivity-determining region (ISDR) were analysed.
|
21068134 |
2011 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Two single nucleotide polymorphisms (SNP, rs8099917, rs12979860) near the IL28B gene have been illustrated as outcome predictors of hepatitis C virus (HCV) treatment with pegylated interferon/ribavirin.
|
22257210 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
TVR given at 12 h intervals should be considered for patients with lower body weight, especially patients with prior relapse and with IL28B polymorphisms at rs8099917 TT (interferon-λ 4 ss469415590 polymorphism TT/TT) genotype in patients with genotype 1b HCV infection.
|
24192751 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To assess whether the IL28B rs8099917 SNP also affects the progression of chronic HCV infection, we genotyped 511 Japanese HCV patients, including 69 with hepatocellular carcinoma (HCC).
|
22245236 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
To analyze the genetic heterogeneity of the Amerindian and admixed population (Mestizos) based on the IL28B (rs12979860, rs8099917) and IFNL4 (rs368234815) haplotypes, and their association with spontaneous clearance (SC) and liver damage in patients with hepatitis C infection from West Mexico.
|
26741362 |
2016 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study suggests that host genetic polymorphisms rs8099917 in the vicinity of IL-28B is the most important predictor of treatment response of PEG-IFN-α/RBV for HCV patients in China.
|
22713131 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study demonstrated that Indonesian patients with chronic hepatitis C (mostly ethnic Java people) mostly were infected with hepatitis C virus (HCV) genotype 1; however, they carried mainly the major genotypes of interleukin 28B (IL-28B) single nucleotide polymorphisms (SNPs) (rs12979860 CC, rs11881222 TT, rs8103142 AA, and rs8099917 TT), and they mostly achieved sustained virological responses to pegylated interferon/ribavirin treatment.
|
24696021 |
2014 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study attempted to demonstrate the role of single and combined IL28B polymorphisms (rs8099917, rs12979860 and rs12980275) and other host and viral factors in predicting response to treatment, in Caucasian patients infected with HCV genotype 1.
|
23831131 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This study aimed at assessing the value of IL28B rs8099917 gene polymorphism in predicting sustained virological response (SVR) among HCV infected Egyptian patients treated with PEG-IFN and RBV.
|
26003758 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
This results demonstrate that in HCV genotype 4-infected patients, rs12979860 (CC) and rs8099917 (TT) genotypes may identify patients who are likely to respond to treatment.
|
25115611 |
2015 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thirty-five percent of patients carrying the CC haplotype and 26% with the TT genotype at SNP rs8099917 showed spontaneous clearance of HCV infection (P = 0.00262 vs. CT/TT; and P = 0.00371 vs. TG/GG respectively).
|
22913807 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These results demonstrate that rs12979860, compared to rs8099917, may be a better predictor of response to the peg-IFN/RBV treatment among HCV/HIV-1 coinfected patients.
|
22328925 |
2012 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
These findings indicate that serum IFNL3 levels at baseline are higher in AHC patients regardless of the rs8099917 polymorphism, and primary HCV infection triggers the production of IFNL3.
|
29040985 |
2017 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
There were significant differences in the reduction of HCV-RNA levels after peg-IFN-α plus ribavirin therapy based on the IL28B SNP rs8099917 between TT (favourable) and TG/GG (unfavourable) genotypes in patients; the first-phase viral decline slope per day and second-phase slope per week in TT genotype were significantly higher than in TG/GG genotype.
|
23135762 |
2013 |
|
Hepatitis C
|
|
0.100 |
GeneticVariation
|
BEFREE |
Then, the impact of the IFNL3 single nucleotide polymorphism genotype (TT/non-TT at rs8099917) on treatment outcomes was evaluated in the 180 patients, and between patients infected with either HCV sub-genotype 2a or 2b.
|
25852275 |
2015 |